Evidence map›Paper›PMID 42865394›Full record

ArticleFrontiers in medicine2026

Real-world anatomical and functional outcomes following Faricimab therapy in neovascular age-related macular degeneration: a one-year observational study.

Settimio Rossi, Carlo Gesualdo, Maria Consiglia Trotta, Raffaele Perrotta, Fabiana Anna D'Agostino, Davide Sabbatino, Claudia Gerosolima, Rosalba Casaburi, Francesca Simonelli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Settimio Rossi *Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Carlo Gesualdo *Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Maria Consiglia TrottaDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Raffaele PerrottaEye Unit, G. Rummo Hospital, Benevento, Italy.
Fabiana Anna D'AgostinoEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Davide SabbatinoEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Claudia GerosolimaEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Rosalba CasaburiEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
Francesca SimonelliEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study evaluated 12-month anatomical and functional outcomes of Faricimab in Italian patients with neovascular age-related macular degeneration (nAMD). Methods: 30 eyes from 30 participants who completed the 12-month follow-up were retrospectively analyzed at "Luigi Vanvitelli" University Eye Clinic (Naples) and "Rummo" Hospital Ophthalmology Unit (Benevento). All underwent best-corrected visual acuity (BCVA), spectral-domain optical coherence tomography (SD-OCT), and optical coherence tomography angiography (OCTA). Patients were stratified by anti-vascular endothelial growth factor (VEGF) treatment [naïve ( Results: The intravitreal injection number was similar between naïve and non-naïve eyes (median, 6 vs. 7; Discussion: This retrospective two-center study showed significant improvements in BCVA and CRT after 12 months of Faricimab, with no statistically detectable difference in longitudinal BCVA according to previous anti-VEGF exposure. Although baseline SHRM was associated with a significant time-by-SHRM interaction for BCVA, the absence of significant multiplicity-adjusted between-group differences limits interpretation of a differential response according to SHRM status. Given the small sample size and retrospective design, these findings should be interpreted cautiously.

Indexed as

Faricimablong-acting drugsneovascular age-related macular degenerationreal-life outcomestreat-and-extend

Identifiers

PMID42865394
PMCPMC13654786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.